Acute Coronary Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Acute Coronary Syndrome is one of the most common diseases in developing countries. It is commonly known as a heart attack, and it occurs when there is a sudden blockage in blood flow in one or more of the coronary arteries, cutting off blood supply to a part of the heart muscle and causing necrosis. If the blockage is severe, the heart may stop beating. This is most commonly caused by occlusion or blockage of a coronary artery caused by a vulnerable atherosclerotic plaque rupture, an unstable collection of lipids and white blood cells in the artery wall. Myocardial infarction usually begins in the endocardium and spreads towards the epicardium. Acute myocardial infarction symptoms include chest pain that may spread to the shoulder, arm, back, neck, or jaw. This type of pain always begins in the center or left side of the chest and lasts a few minutes. The onset of symptoms in acute myocardial infarction is usually gradual, over several minutes, and rarely instantaneous.

The incidence of Acute Coronary Syndrome ranges from 189 to 225 cases per 100,000 population in the USA.

The competitive landscape of Acute Coronary Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Acute Coronary Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Coronary Syndrome Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Acute Coronary Syndrome – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          dalcetrapib        DalCor Pharmaceuticals Phase 3

2          E5555   Eisai Inc.          Phase 2

3          Inclisiran           Novartis Pharmaceuticals          Phase 3

4          Apolipoprotein A-I          CSL Behring     Phase 3

5          Losmapimod     GlaxoSmithKline            Phase 3

6          TAK-442           Takeda Phase 2

7          MDCO-216       The Medicines Company           Phase 2

8          Alirocumab        Regeneron Pharmaceuticals      Phase 3

9          LC23-1306        LG Life Sciences           Phase 1

10        SP-8008           Shin Poong Pharmaceutical Co. Ltd.      Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more